Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Debt to Equity (2016 - 2025)

Cytosorbents' Debt to Equity history spans 9 years, with the latest figure at $2.82 for Q4 2025.

  • Quarterly results put Debt to Equity at $2.82 for Q4 2025, up 124.07% from a year ago — trailing twelve months through Dec 2025 was $2.82 (up 124.07% YoY), and the annual figure for FY2025 was $2.82, up 124.07%.
  • Debt to Equity for Q4 2025 was $2.82 at Cytosorbents, up from $1.61 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $2.82 in Q4 2025 to a low of $0.14 in Q4 2022.
  • The 4-year median for Debt to Equity is $0.88 (2024), against an average of $0.9.
  • The sharpest move saw Debt to Equity soared 51.95% in 2023, then surged 486.72% in 2024.
  • Year by year, Debt to Equity stood at $0.14 in 2022, then surged by 51.95% to $0.21 in 2023, then surged by 486.72% to $1.26 in 2024, then soared by 124.07% to $2.82 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $2.82, $1.61, and $1.24 for Q4 2025, Q3 2025, and Q2 2025 respectively.